Diseases & Conditions
Grants & Contracts
News & Events
December 19, 2019
A new study finds that an NIH-developed Zika vaccine improves fetal outcomes in an animal model.
December 19, 2019
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group. NIAID intends to provide approximately $29 million per year for seven years for the VTEU program and its companion leadership group.
December 18, 2019
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases. The observational study included neuropsychological evaluations of 611 children in sub-Saharan Africa.
December 13, 2019
As antibiotic-resistant bacteria become more urgent threats worldwide, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will provide up to $102.5 million in renewed funding over seven years for the Antibacterial Resistance Leadership Group (ARLG). This global consortium of scientific experts leads a comprehensive clinical research network overseeing research on important scientific questions related to antibacterial resistance.
December 11, 2019
Efforts to prevent new HIV transmissions in the United States must be accompanied by advances in addressing HIV-associated comorbidities to improve the health of people already living with HIV, National Institutes of Health experts assert in the third of a series of JAMA commentaries.
December 10, 2019
A new strategic plan from NIH outlines future HBV research with the goals of developing a cure and improving scientific understanding.
December 05, 2019
Extensive evidence from HIV prevention research studies has firmly established that “Undetectable Equals Untransmittable,” or U=U. This means that people living with HIV who achieve and maintain an undetectable viral load—the amount of virus in their blood—by taking antiretroviral therapy (ART) as prescribed do not sexually transmit HIV to others. The U.S.
November 27, 2019
NIAID discusses a new report which shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.
November 26, 2019
Scientists have determined that La Crosse virus (LACV), which can cause inflammation of the brain in children, affects brain cells differently depending on their developmental stage. Neurons—the primary brain cells of the central nervous system—evolve from neural stem cells and during development “commit” to becoming neurons. A new National Institutes of Health study shows that uncommitted neural stems cells generally survive LACV infection, while LACV often kills neurons. The study also shows that neurons infected by LACV can be rescued by interferon, a powerful antiviral protein.
November 25, 2019
Earlier this year, President Donald J. Trump made a bold commitment during his State of the Union Address to end the HIV epidemic in the United States. Subsequently, the U.S. Department of Health and Human Services launched an ambitious plan called Ending the HIV Epidemic: A Plan for America to reduce the incidence of HIV domestically by 75% in 5 years, and by 90% by 2030.
November 20, 2019
Although eastern equine encephalitis (EEE), a mosquito-borne illness, has existed for centuries, 2019 has been a particularly deadly year for the disease in the United States. As of November 12, 36 confirmed cases of EEE had been reported by eight states; 13 of these cases were fatal.
November 08, 2019
NIH scientists have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses.
November 04, 2019
Investigators at the National Institutes of Health have found that sesame allergy is common among children with other food allergies, occurring in an estimated 17% of this population. In addition, the scientists have found that sesame antibody testing—whose utility has been controversial—accurately predicts whether a child with food allergy is allergic to sesame. The research was published on Oct. 28 in the journal Pediatric Allergy and Immunology.
October 25, 2019
A set of three antibodies identified by NIAID could lead to better treatments and vaccines against influenza, according to a paper published this week.
October 24, 2019
Optimal implementation of existing HIV prevention and treatment tools and continued development of new interventions are essential to ending the HIV pandemic, National Institutes of Health experts write in a commentary in Clinical Infectious Diseases.
October 23, 2019
A NIAID clinical trial aims to assess how levels of pre-existing influenza antibodies impact a volunteer’s flu symptoms following exposure to influenza.
October 18, 2019
A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine—approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC)—remains fully protective against disease in experimentally infected monkeys, according to National Institutes of Health scientists. The NIH investigators completed the vaccine dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16.
October 16, 2019
NIH scientists have developed an ultrasensitive new test to detect abnormal forms of the protein Tau associated with uncommon brain diseases.
October 16, 2019
A new NIAID-supported study describes a new rapid assay for Lyme disease that could lead to a practical test for use by healthcare providers.
October 11, 2019
Researchers at the National Institutes of Health and their colleagues at Massachusetts General Hospital (MGH) in Boston report that the injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV. The study was conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute, both parts of NIH. The findings were published online today in The Lancet HIV.
October 04, 2019
A 5-minute soak in a 40% solution of household bleach decontaminated stainless steel wires coated with chronic wasting disease (CWD) prions, according to a new study by National Institutes of Health scientists. The scientists used the wires to model knives and saws that hunters and meat processors use when handling deer, elk and moose – all of which are susceptible to CWD. The research was conducted at Rocky Mountain Laboratories (RML) in Hamilton, Mont. RML is a component of the NIH’s National Institute of Allergy and Infectious Diseases.
October 02, 2019
People living with HIV who received kidney transplants from deceased donors with HIV had high rates of overall survival and kidney graft survival after five years, according to an observational study published online today in The New England Journal of Medicine. The study, which incorporated data from transplants beginning in 2008, was a collaboration of researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S.
October 02, 2019
Study results published today help clarify how to safely prevent tuberculosis (TB) in women living with HIV who are pregnant or have recently given birth, are taking antiretroviral therapy, and live where TB is highly prevalent.
October 01, 2019
A new study published today online in Emerging Infectious Diseases suggests that transmission of a protozoan parasite from insects may also cause leishmaniasis-like symptoms in people. The parasite, however, does not respond to treatment with standard leishmaniasis drugs. The research was conducted by scientists at the Federal Universities of Sergipe and São Carlos, the University of São Paulo, and the Oswaldo Cruz Foundation, all in Brazil, along with investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S.
September 30, 2019
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years.